Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Dr. Lal Pathlabs Ltd

NSE: LALPATHLAB · BSE: 539524 · Healthcare · 56 announcements

Share price
₹1,948.90
Market cap
₹32,712 Cr
Revenue (annual)
₹2,763 Cr
Net profit (annual)
₹504.8 Cr
P/E (TTM)
60.4×Sector 53.1×
Promoter holding
53.19%-0.02% QoQ
FII holding
17.35%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

17:07 IST NSE
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹38 Cr

Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.

Value
₹38.00 Cr
16:54 IST NSE
Acquisition

Dr. Lal Pathlabs Acquisition

Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.

18:49 IST BSE
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹168 Cr

Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.

Value
₹168.0 Cr
17:20 IST BSE
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹199.5 Cr

Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.

Value
₹199.5 Cr
19:20 IST NSE
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹3.5 Cr

Dr. Lal Path Labs Ltd.'s subsidiary completed a 30% stake subscription in Neuome Technologies Private Limited for ₹3.50 Crore, making Neuome an associate company.

Value
₹3.50 Cr
19:11 IST BSE
Acquisition

Dr. Lal Pathlabs Acquisition

Dr. Lal PathLabs' subsidiary, Dr. Lal Ventures, has completed the acquisition of a 30% stake in Neuome Technologies Private Limited.

18:32 IST BSE
Acquisition

Dr. Lal Pathlabs Acquisition

Dr. Lal Path Labs Ltd.'s subsidiary will acquire a 70% stake in Dr Lal PathLabs Indomed LLC to expand its diagnostics services in Uzbekistan.

19:55 IST NSE
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹20 Cr

Dr. Lal Path Labs Ltd. has completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) for ₹20 Crore. Following the transaction, SDCPL has become a wholly owned subsidiary of the company. This acquisition strengthens the company's diagnostic footprint.

Value
₹20.00 Cr
19:17 IST NSE
Acquisition

Dr. Lal Pathlabs Acquisition

Dr. Lal PathLabs Ltd. has successfully completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) on May 01, 2026. SDCPL is now a wholly-owned subsidiary of the company, following the terms of the Share Purchase Agreement signed on April 30, 2026.

18:05 IST NSE
Acquisition

Dr. Lal Pathlabs Acquisition Worth ₹20 Cr

Dr. Lal Path Labs Ltd. will acquire a 100% stake in Mumbai-based Shahbazkers Diagnostic Centre Private Limited for ₹20 Crore. The cash transaction is expected to conclude by May 31, 2026. This acquisition aims to strengthen the company’s diagnostic service presence in Mumbai, Maharashtra.

Value
₹20.00 Cr
Execution
By May 31, 2026